Clinical trials
Phase 2 Study clinical trials
Below are recruiting phase 2 study clinical trials, each written for real people, not researchers. We’re tracking 1,327 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07189169RecruitingPhase 3
Testing QA108 for intermediate AMD
This trial tests an investigational medicine (QA108) for people with intermediate age-related macular degeneration (AMD). It aims to slow or prevent progression of the disease by treating the deposits (drusen) in the center of the retina.
BeijingAges 45–85 - NCT07190833RecruitingPhase 1
Study of a cancer-killing virus injection for solid tumors
This early-phase trial tests a cancer-killing virus (OTS-412) that is injected directly into tumors. It is for people with solid tumors that have not responded to standard treatments, including immunotherapy. The goal is to see if the virus can shrink or control the injected tumors.
BusanAges 19 years+ - NCT06587802RecruitingPhase 2
PD-1 antibody and radiation for advanced adrenal cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT07181837RecruitingPhase 1/Phase 2
Testing MVX-220 for Angelman Syndrome
This study tests an experimental medicine called MVX-220 to see if it is safe and effective for people with Angelman Syndrome. It includes both children (ages 4-8) and adults (ages 18-50) who can walk independently and have stable seizure medications.
Los Angeles, CaliforniaAges 4–50 - NCT07182682RecruitingPhase 3
Sunvozertinib after surgery for early-stage NSCLC with certain EGFR mutations
This trial tests the drug sunvozertinib given after surgery to see if it prevents lung cancer from coming back. It is for people with early-stage non-small cell lung cancer that has specific changes in the EGFR gene (exon20 insertion or PACC mutations).
BeijingAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+ - NCT07170995RecruitingPhase 3
Study of SHR-8068 with adebrelimab and chemo for lung cancer
This trial tests a new combination of drugs (SHR-8068 plus adebrelimab and chemotherapy) against another approved combination for people with advanced non-small cell lung cancer who have not had treatment yet. The goal is to see which combination works better.
Jinan, ShandongAges 18–75 - NCT07171606RecruitingPhase 2
Study of a new drug for advanced lung cancer
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
ShanghaiAges 18–75 - NCT07171034RecruitingPhase 1
Testing KLA318-2 in healthy volunteers
This study tests a new drug called KLA318-2 in healthy volunteers to see how it is processed by the body and how safe it is. It is a first-in-human trial, so it helps find the right dose and check for any side effects.
Jinan, ShandongAges 18–45 - NCT07169487RecruitingPhase 1
Methylene Blue for Side Effects of Cancer Immunotherapy
This trial tests if methylene blue can help people who develop side effects called CRS or ICANS after treatments like CAR-T cells or bispecific antibodies. It is a first-in-human study to find a safe dose.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05908409RecruitingPhase 1/Phase 2
Testing an investigational drug for blood cancers that came back
This Phase 1/2 trial tests IDP-121 in people with certain blood cancers that have returned or did not respond to available treatments. The goal is to find a safe dose and see whether the treatment can help control the cancer.
Santander, CantabriaAges 18 years+ - NCT06954558RecruitingPhase 1
GK01 for advanced solid tumors that are hard to treat
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
TianjinAges 18–70 - NCT07158775RecruitingPhase 1/Phase 2
BS01 gene therapy for dry age-related macular degeneration
This trial tests a new gene therapy, BS01, given as an eye injection. It is for people with advanced dry age-related macular degeneration (AMD) that has caused geographic atrophy—damage to the central part of the retina. The study aims to see if the treatment is safe and can help slow vision loss.
Edison, New JerseyAges 50–85 - NCT07158710RecruitingPhase 1
Study of HSK42360 for brain tumors with BRAF V600 mutation in children
This trial tests a new drug, HSK42360, for children with recurrent brain tumors that have a specific gene change called BRAF V600. The goal is to see if the drug can help when standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07157033RecruitingPhase 1/Phase 2
Testing XER-001 with radiation for advanced pancreatic cancer
This trial tests a new way to deliver a drug called amifostine (XER-001) alongside intense radiation therapy (SBRT) for people with locally advanced pancreatic cancer that can't be surgically removed. The goal is to see if it's safe and effective at protecting healthy tissue while targeting the tumor.
Duarte, CaliforniaAges 18 years+ - NCT07154706RecruitingPhase 3
Taletrectinib vs placebo after surgery for ROS1-positive lung cancer
This trial tests whether taletrectinib (a targeted pill) can help prevent lung cancer from coming back after surgery in people whose tumors have a ROS1 gene change. You would take either taletrectinib or a placebo (inactive pill) for about a year after surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT07148180RecruitingPhase 1/Phase 2
Targeting leftover leukemia cells with a combination therapy
This trial tests a new drug combo (tagraxofusp, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) who have very small amounts of cancer cells still present after initial treatment. The goal is to see if it can clear these leftover cells and prevent the cancer from coming back.
Boston, MassachusettsAges 18 years+ - NCT07142980RecruitingPhase 1
Study of HRS-7172 for advanced solid tumors with RAS mutations
This trial tests a new drug, HRS-7172, for people with advanced solid tumors that have RAS mutations or amplifications. It aims to see if the drug is safe and effective for these cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07140809RecruitingPhase 1/Phase 2
Study of JMT202 for people with high triglycerides
This trial tests a new injectable drug, JMT202, for people with high triglycerides (a type of fat in the blood). The goal is to see if it safely lowers triglycerides and may reduce heart risk.
Beijing, Beijing MunicipalityAges 18–75 - NCT07135466RecruitingPhase 1/Phase 2
Anti-CD22 CAR T-cell therapy for B-cell blood cancers
This trial tests a new treatment using your own immune cells (T-cells) that are modified to find and attack cancer cells with a marker called CD22. It is for people with B-cell blood cancers that have come back or not responded to at least two prior treatments, including a type of immunotherapy called CAR T-cell therapy.
Ramat Gan, GAges 1–80 - NCT07134998RecruitingPhase 1
Study of HRS-6093 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07134153RecruitingPhase 1/Phase 2
T-DXd injected into spinal fluid for HER2 breast cancer with brain spread
This trial tests a new way of giving the targeted drug T-DXd—directly into the fluid around your spine (intrathecal) or through a device under your scalp called an Ommaya reservoir. It's designed for people with HER2-positive breast cancer that has spread to the brain or the lining of the brain/spinal cord.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06634394RecruitingPhase 1
Study of APVO436 for untreated AML patients
This trial tests a new drug called APVO436 for people with a type of acute myeloid leukemia (AML) that has not been treated before. It is for those who cannot receive strong standard chemotherapy due to age, health problems, or organ function issues.
Denver, ColoradoAges 18 years+ - NCT07118527RecruitingPhase 3
New drug combo for untreated advanced stomach cancer
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
Shenyang, LiaoningAges 18–75
Hear when a new Phase 2 Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 2 study?
- Yes. Clin2 currently lists 1,327 recruiting phase 2 study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 2 study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 2 study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.